Avenge Bio

Avenge Bio was founded by an experienced team of proven biotech executives to develop transformative therapeutics which can potentially eradicate intractable solid tumors. Avenge Bio is developing our proprietary, allogeneic LOCOcyteTM platform for precision delivery of cytokines and other highly potent immunomodulatory molecules for a controlled period of time. Through this approach we are able to generate robust, local and systemic anti-tumor immune responses, without the toxicities associated with traditional immunotherapies. The LOCOcyteTM platform was developed from extensive research and experience of Dr. Omid Veiseh at Rice University and supported by Longitude Capital, CAM Capital, Perceptive Xontogeny, Rock Springs, Pappas Capital, and other leading healthcare investors. Together we are using the strength and efficiency of our platform to create a broad pipeline of therapeutics that target a wide range of difficult to treat solid tumors.

Avenge Bio

Follow our Spotify playlists link in bio 🔥 Checkout @asmodaiband DM for promotion! Follow @asmodaiart Follow @asmodaiband 😈 Follow…

Avenge Bio Receives FDA Orphan Drug Designation for AVB-001 for the Treatment of Mesothelioma

avengebio (@AvengeBio) / X

BioCentury - Asif Ali to join Protagonist as CFO

Avenge Bio Developing Cell Generated Immunotherapies to Eradicate Solid Tumors

Avenge Bio Developing Cell Generated Immunotherapies to Eradicate Solid Tumors

Avenge Bio on LinkedIn: #asco23

Avenge Bio Developing Cell Generated Immunotherapies to Eradicate Solid Tumors

avenge worldwide｜TikTok Search

Avenge Bio Developing Cell Generated Immunotherapies to Eradicate Solid Tumors

Michael Heffernan on LinkedIn: Avenge Bio Presents Preclinical Data at the American Society of Gene &…